Adial Pharmaceuticals Closes Acquisition of Purnovate
Acquisition Expands Adial’s Portfolio with Drug Candidates for Treatment of Pain and Addiction CHARLOTTESVILLE, VA / ACCESSWIRE / January 26, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company more...
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded more...
Cardiff Oncology Receives “Study May Proceed” from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Cardiff Oncology Receives “Study May Proceed” from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) – Trial will evaluate the safety and efficacy of onvansertib in combination with standard-of-care more...
ADMA Biologics Receives Unique Permanent J-Code for ASCENIV(TM)
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the more...
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol’s Novel Anti-Fibrotic Mechanism of Action
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol’s Novel Anti-Fibrotic Mechanism of Action – Galmed KOL Symposium and Pipeline Update taking place later today at 11 a.m. Eastern time PR more...
New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class
— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors — Data differentiates ASLAN003 from first generation DHODH inhibitors and more...
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients
Topline Data from Phase 2b OPTION 2 Trial Expected in First Quarter 2021 DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) — Az u rRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company more...
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development
Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects” WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) more...
Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously more...
Caladrius Biosciences Closes $25.0 Million Private Placement
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced more...